TARPEYO Reduces the Loss of Kidney Function in IgA Nephropathy

The US Food and Drug Administration (FDA) Recently announced full approval of TARPEYO® (budesonide) delayed release capsules to reduce the loss of kidney function in adults with primary IgA nephropathy (IgAN). TARPEYO’s full FDA approval is a significant milestone for the IgAN community. The full approval is based on the 2-year results of the global phase 3 NefIgArd study, the first and only Phase 3 IgAN trial to show confirmed, statistically significant benefit over placebo in eGFR sustained over a 2-year period. Nephrology Times spoke with Richard Lafayette, MD, FACP, the primary investigator of the NefIgArd trial, about the study, and the clinical impact of TARPEYO on the nephrology community.